Treatment of Rheumatoid Arthritis With Anti-Tumor Necrosis Factor or Tocilizumab Therapy as First Biologic Agent in a Global Comparative Observational Study
Author:
Affiliation:
1. Cardiff University; Cardiff UK
2. F. Hoffmann-La Roche; Basel Switzerland
3. Centro Integral de Reumatología Reumalab; Medellín Colombia
4. S. C. Reumatologia, A. O. Ospedale Niguarda Ca' Granda; Milan Italy
Funder
Roche
Publisher
Wiley
Subject
Rheumatology
Reference29 articles.
1. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis;Singh;Arthritis Rheumatol,2016
2. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update;Smolen;Ann Rheum Dis,2014
3. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial;Gabay;Lancet,2013
4. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial;Schiff;Ann Rheum Dis,2014
5. Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority trial;Porter;Lancet,2016
Cited by 38 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Comparative effectiveness of treatments for rheumatoid arthritis in clinical practice: A systematic review;Seminars in Arthritis and Rheumatism;2023-10
2. The impact of COVID-19 and other factors on the usage status of the biologic drug therapies for rheumatoid arthritis: A study from Vietnam;Reumatología Clínica;2023-10
3. Real-world Comparative Effectiveness of Methotrexate-based Combinations for Rheumatoid Arthritis: A Retrospective Cohort Study;Clinical Therapeutics;2023-09
4. Reduced C-reactive protein level at hospital admission in patients treated with Tocilizumab – An attention may be required;Heliyon;2023-06
5. Role of JAK-STAT signaling pathway in pathogenesis and treatment of primary Sjögren's syndrome;Chinese Medical Journal;2023-04-25
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3